Demonstration of reduction of IL-6 levels in aqueous has been shown to be an important marker for reduction of vascular endothelial growth factor (VEGF) in patients with diabetic retinopathy on bevacizumab (anti VGEF treatment) [21, 22]. Here, VEGFA is linked to diabetic retinopathy.